Royalty Pharma Plc (RPRX)

Currency in USD
57.72
+0.24(+0.42%)
Closed·
57.70-0.05(-0.09%)
·
Advertisement
Earnings results expected today
RPRX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
57.4159.63
52 wk Range
34.0860.44
Key Statistics
Prev. Close
57.48
Open
59.53
Day's Range
57.41-59.63
52 wk Range
34.08-60.44
Volume
3.1M
Average Volume (3m)
3.63M
1-Year Change
52.2553%
Book Value / Share
16.08
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
RPRX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
61.63
Upside
+6.77%
Members' Sentiments
Bearish
Bullish
ProTips
Has raised its dividend for 6 consecutive years

Royalty Pharma Plc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Neutral
Moving Averages
Sell

Analyst Ratings

6 Buy
2 Hold
0 Sell
Ratings:
8 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 61.63
(+6.77% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
BofA Securities
Buy63.00+9.15%62.00Maintain05/08/2026
JPMorgan
Buy58.00+0.49%50.00Maintain07/05/2026
Morgan Stanley
Buy64.00+10.88%63.00Maintain07/05/2026
Goldman Sachs
Buy59.00+2.22%51.00Maintain07/05/2026
UBS
Buy57.00-1.25%51.00Maintain21/04/2026

Royalty Pharma Plc Earnings Call Summary for Q2/2026

  • Royalty Pharma posted Q2 portfolio receipts of $773M, up 6% YoY, with total receipts rising 14%, marking 25th consecutive quarter of growth.
  • Company raised FY2026 guidance for second straight quarter: portfolio receipts now $3.4B-$3.5B, royalty receipt growth lifted to 7%-10% from 4%-8%.
  • Firm maintains $4B+ financial flexibility with BBB ratings across all three major credit agencies; leverage stands at 2.8x debt-to-EBITDA.
  • Management reaffirmed 2030 target of $4.7B in portfolio receipts, highlighting expansion in development-stage assets and China opportunities.
  • Stock rose 0.63% to $57.84 in premarket trading, near 52-week high of $60.44, reflecting solid but largely anticipated results.
Last Updated: 05/08/2026, 14:10
Read Full Transcript

Earnings

Latest Release
05/08/2026
EPS / Forecast
1.32 / 1.29
Revenue / Forecast
773M / 800.05M
EPS Revisions
Last 90 days

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 1.90%
Dividend Yield
1.64%
Industry Median 2.33%
Annualised payout
0.94
Paid quarterly
5-Years Growth
+13.75%
Growth Streak

Compare RPRX to Peers and Sector

Metrics to compare
RPRX
Peers
Sector
Relationship
P/E Ratio
30.8x12.3x−0.4x
PEG Ratio
−1.38−0.760.00
Price/Book
4.8x3.5x2.6x
Price / LTM Sales
13.6x2.3x3.0x
Upside (Analyst Target)
7.0%19.4%51.9%
Fair Value Upside
Unlock−3.6%7.2%Unlock

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company has research and development funding collaboration to advance the development of JNJ-4804, an investigational medicine for autoimmune diseases. The company was founded in 1996 and is based in New York, New York.

Employees
100

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
184.63M41.65%10.56B
Other Institutional Investors
187.79M42.36%10.74B
Public Companies & Retail Investors
70.86M15.99%4.05B
Total
443.27M100.00%25.34B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Capital Research and Management Company10.33%45,809,1332,618,908
Morgan Stanley Investment Management Inc.8.33%36,931,1082,111,351

People Also Watch

18.080
HMY
+7.11%
380.78
RL
+0.76%
408.74
CIEN
-0.58%
224.63
CRDO
-5.59%
17.16
USAR
-0.67%

FAQ

What Is the Royalty Pharma (NASDAQ: RPRX) Share Price Today?

The Royalty Pharma stock price today is 57.72 USD.

What Stock Exchange Does Royalty Pharma (RPRX) Trade On?

Royalty Pharma is listed and trades on the Nasdaq Stock Exchange.

What Is the Ticker (Stock Symbol) for Royalty Pharma?

The stock symbol (also called a 'ticker') for Royalty Pharma is "RPRX."

Does Royalty Pharma Pay Dividends? What’s The Current RPRX Dividend Yield?

Yes, RPRX Pays Dividends to its Shareholders. The current Royalty Pharma dividend yield is 1.63%.

What Is the Current Royalty Pharma Market Capitalisation?

As of today, Royalty Pharma (NASDAQ: RPRX) market cap is 33.10B USD.

What Is Royalty Pharma's (RPRX) Earnings Per Share (TTM)?

The Royalty Pharma EPS is currently 1.90 (Trailing Twelve Months).

When Is the Next Royalty Pharma Earnings Date?

Royalty Pharma's next earnings report will be released on 05/08/2026.

Is RPRX a Buy or Sell From a Technical Analyst Perspective?

Based on today's Royalty Pharma moving averages and other technical indicators, the daily buy/sell signal for RPRX stock is Neutral.

How Many Times Has Royalty Pharma Stock Split?

Royalty Pharma has split 0 times. (See the RPRX stock split history page for full effective split date and price information.)

How Many Employees Does Royalty Pharma Have?

Royalty Pharma has 100 employees, based on their latest Companies House report.

What is the current trading status of Royalty Pharma (NASDAQ: RPRX)?

As of 05/08/2026, Royalty Pharma (RPRX) is trading at a share price of 57.72 USD, with a previous close of 57.48 USD. The stock has fluctuated within a day range of 57.41 USD to 59.63 USD, while its 52-week range spans from 34.08 USD to 60.44 USD.

What Is Royalty Pharma (RPRX) Price Target According to Analysts?

The average 12-month price target for Royalty Pharma is 61.63 USD, with a high estimate of 66 USD and a low estimate of 58 USD. 6 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +6.77% Upside potential.

What Is the RPRX Premarket Price?

RPRX's last pre-market stock price is 59.11 USD. The pre-market share volume is 6,560.00, and the stock has decreased by 1.63, or 2.84%.

What Is the RPRX After Hours Price?

RPRX's last after hours stock price is 57.70 USD, the stock has decreased by -0.05, or -0.09%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.